PROTAC ER Degrader-2

• UNSPSC Description:

  PROTAC ER Degrader-2 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab)[1].

• Target Antigen:

  Estrogen Receptor/ERR; PROTACs

• Type:

  Reference compound

• Related Pathways:

  PROTAC;Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/protac-er-degrader-2.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C(COCCOCCNC(C3=CC=C(C(N4[C@@H](C)[C@H](NC([C@H](C)N(C(OC(C)(C)C)=O)C)=O)C(N(CC5=C(OC)C=CC6=C5C=CC=C6)C7=C4C=C(C#N)C=C7)=O)=O)C=C3)=O)=O)C=C2)\C8=CC=C(OCC9=CC=C(NC([C@@H](NC([C@H](C(C)C)N)=O)CCCNC(N)=O)=O)C=C9)C=C8

• Molecular Weight:

  1581.85

• References & Citations:

  [1]Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported